We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+32.76%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$5.72B
AUM Growth
+$1.24B
Cap. Flow
+$495M
Cap. Flow %
8.66%
Top 10 Hldgs %
39.54%
Holding
129
New
28
Increased
37
Reduced
19
Closed
17

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$84.9M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$72.9M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$65.7M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$65.1M
5
PCVX icon
Vaxcyte
PCVX
+$58.5M

Top Sells

Rank Stock Value
1
LIAN
LianBio American Depositary Shares
LIAN
+$257M
2
CBAY
Cymabay Therapeutics
CBAY
+$95.1M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$46.3M
4
ACLX
Arcellx
ACLX
+$38.8M
5
ABBV icon
AbbVie
ABBV
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.28%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRCT icon
76
Procept Biorobotics
PRCT
$1.03B
$10.4M 0.18%
+210,659
New +$10M
MORF
77
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$10.1M 0.18%
288,221
+231,241
+406% +$7.75M
SPRY icon
78
ARS Pharmaceuticals
SPRY
$574M
$8.86M 0.16%
+867,319
New +$6.47M
ARQT icon
79
Arcutis Biotherapeutics
ARQT
$3.53B
$7.43M 0.13%
+750,000
New +$5.6M
AVBP icon
80
ArriVent BioPharma
AVBP
$1.39B
$7.41M 0.13%
+415,000
New +$8.37M
DTIL icon
81
Precision BioSciences
DTIL
$176M
$6.52M 0.11%
+480,483
New +$5.88M
COGT icon
82
Cogent Biosciences
COGT
$6.86B
$5.94M 0.1%
883,333
-239,625
-21% -$1.48M
KALV
83
DELISTED
KalVista Pharmaceuticals
KALV
$5.93M 0.1%
+500,000
New +$6.67M
IBRX icon
84
ImmunityBio
IBRX
$7.25B
$5.65M 0.1%
+1,052,887
New +$4.77M
MGNX icon
85
MacroGenics
MGNX
$238M
$5.57M 0.1%
378,327
-233,605
-38% -$3.53M
BBOT
86
BridgeBio Oncology
BBOT
$683M
$5.2M 0.09%
+500,000
New +$5.18M
XFOR icon
87
X4 Pharmaceuticals
XFOR
$381M
$4.93M 0.09%
118,182
– –
AMLX icon
88
CALL
Amylyx Pharmaceuticals
AMLX
$2.21B
$4.77M 0.08%
+1,679,125
New +$22M
XBI icon
89
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$4.74M 0.08%
50,000
-1,850,000
-97% -$172M
ESTA icon
90
Establishment Labs
ESTA
$2.74B
$4.19M 0.07%
82,299
– –
NAMS icon
91
NewAmsterdam Pharma
NAMS
$3.27B
$4.14M 0.07%
+175,000
New +$3.55M
ABSI icon
92
Absci
ABSI
$1.18B
$3.98M 0.07%
+700,000
New +$3.15M
VERU icon
93
Veru
VERU
$35.8M
$3.91M 0.07%
558,470
– –
KYTX icon
94
Kyverna Therapeutics
KYTX
$439M
$3.73M 0.07%
+150,000
New +$4.19M
TRIB
95
Trinity Biotech
TRIB
$8.69M
$3.67M 0.06%
+60,000
New +$4.22M
NBTX
96
Nanobiotix
NBTX
$1.9B
$3.61M 0.06%
555,066
– –
APLT
97
CALL
DELISTED
Applied Therapeutics
APLT
$3.4M 0.06%
500,000
– –
NVNO
98
enVVeno Medical
NVNO
$6.94M
$3.39M 0.06%
17,809
– –
NVAX icon
99
PUT
Novavax
NVAX
$1.22B
$3.35M 0.06%
700,000
-700,000
-50% -$3.25M
IMVT icon
100
CALL
Immunovant
IMVT
$7.99B
$3.23M 0.06%
+100,000
New +$3.65M
2 3
4
5 6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Perceptive Advisors held 129 positions worth $5.72B, up 28% from $4.48B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Perceptive Advisors deployed $495M of net new capital in Q1 2024, opening 28 new positions and adding to 37 existing holdings. Its largest new stake was CG Oncology: 1,304,105 shares worth $57.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcellx, an estimated $38.8M trimmed.

  • Perceptive Advisors's largest Q1 2024 buy was CG Oncology: 1,304,105 shares worth $57.3M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q1 2024, an estimated $84.9M increase.
  • Perceptive Advisors's biggest Q1 2024 reduction was Arcellx, cutting an estimated $38.8M.
  • Perceptive Advisors fully exited LianBio American Depositary Shares in Q1 2024, selling an estimated $257M.
  • Perceptive Advisors's ten largest holdings make up 40% of its $5.72B portfolio in Q1 2024.
  • Perceptive Advisors opened 28 new positions and closed 17 in Q1 2024.
  • Perceptive Advisors's portfolio value rose 28% quarter-over-quarter to $5.72B.

Based on Perceptive Advisors's 13F filing for Q1 2024, filed 15 May 2024.